Anterios (ANTE) Postponed

Developing a topical formulation of botulinum toxin.

Health Care -

IPO Performance
Latest Trade ()
First Day Return
Return from IPO
 
Anterios IPO News more
  • .
IPO Data
IPO File Date 03/31/2015
Offer Price
Price Range $12.00 - $14.00
Offer Shares (mm) 3.9
Deal Size ($mm) $51
 
IPO Data
IPO Date
Offer Price
Price Range $12.00 - $14.00
Offer Shares (mm) 3.9
Deal Size ($mm) $$51
 
Underwriters
more
Business Overview
We are a clinical stage biopharmaceutical company focused on the development, manufacturing and commercialization of novel botulinum products for therapeutic and aesthetic applications. The botulinum toxin type A, or botulinum, market is currently a $2.8 billion global market. All currently approved and commercially available botulinum products are administered by injection. Our lead product candidate, ANT-1207, is a ready-to-use topical formulation of botulinum, which we are developing for the treatment of primary axillary hyperhidrosis, or excessive underarm sweating, facial acne, and lateral canthal lines, also called "crow's feet" wrinkles. We believe that, with ANT-1207, we have the potential to expand the botulinum market by increasing the use of botulinum in currently approved indications and by pursuing new indications, such as acne. We have exclusive patent rights covering the use of botulinum for the treatment of acne. We have successfully completed multi-center, double-blind, randomized clinical trials of ANT-1207 in hyperhidrosis, acne and wrinkles and are currently planning Phase 2b clinical trials in each indication.
We are a clinical stage biopharmaceutical company focused on the development, manufacturing and commercialization of novel botulinum products for therapeutic and aesthetic applications. The botulinum toxin type A, or botulinum, market is currently a $2.8 billion global market. All currently approved and commercially available botulinum products...
more
Company Data
Headquarters New York, NY
Founded 2006
Employees 7
Website www.anteriosinc.com
 

Performance vs. IPO Index (IPOUSA)